[Application of serum hepatitis B virus large surface protein determination in lamivudine anti-viral therapy for patients with hepatitis B].
OBJECTIVE
To study the correlation between serum hepatitis B virus large surface protein (HBV-LP) and hepatitis B virus DNA (HBV-DNA) load in hepatitis B patients treated with lamivudine, and the application of serum HBV-LP measurement in evaluation of lamivudine therapeutic effect and end point judgement.


METHODS
HBV DNA was detected by fluorescent quantitative PCR (FQ-PCR), serum HBV-LP was detected by enzyme linked immunosorbent assay (ELISA).


RESULTS
Both HBV-DNA and HBV-LP decreased in patients responding to lamivudine therapy, and HBV-LP turned negative 3 months later than HBV-DNA. In patients resistant to lamivudine therapy, neither HBV-DNA nor HBV-LP turned negative. In patients whose symptoms relapsed, HBV-LP didn't turn negative, while HBV-DNA was undetectable only transitorily.


CONCLUSIONS
Measuring serum HBV-LP dynamically can be useful in evaluation of lamivudine therapeutic effect.
Li
Guang-yi
GY
People's Hospital of Anji County, Zhejiang Province, Anji, Zhejiang, China.
Sheng
Jiang-li
JL
Huang
Hai-jun
HJ
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D016896:Treatment Outcome; D014759:Viral Envelope Proteins / Q000097:blood*; D055815:Young Adult
D000998:Antiviral Agents; D004279:DNA, Viral; C096362:L protein, hepatitis B virus; D014759:Viral Envelope Proteins; D019259:Lamivudine